Concepedia

Author

Heinz Schmidli

Novartis (Switzerland)ORCID

Also Known As

H Schmidli, H. Schmidli, Heinz Schmidli, Schmidli, Heinz, T. Friede

109

Publications

3.8K

Citations

35

H-Index

94

Concepts

All Affiliations

Novartis (Switzerland)Universitätsmedizin GöttingenNovartis (United States)Medical University of ViennaMedizinische Hochschule Hannover
HS

About

Heinz Schmidli is an author at Novartis (Switzerland) specializing in statistics, medicine, and clinical trials.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

15

786

2

Public Health

13

15

951

3

Engineering

10

10

517

4

Health Sciences

6

6

416

5

Management

1

1

23

Heinz Schmidli

×

58

Publications

3.3K

Citations

32

H-Index

YearCitations

Robust meta‐analytic‐predictive priors in clinical trials with historical control information

Heinz Schmidli, Sandro Gsteiger, Satrajit Roychoudhury,

Biometrics

2014

436

Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts

Frank Bretz, Heinz Schmidli, Franz König,

Biometrical Journal

2006

257

Safety, Tolerability, and Efficacy of Everolimus in De Novo Liver Transplant Recipients: 12- and 36-Month Results

Gary Levy, Heinz Schmidli, Jeffrey D. Punch,

Liver Transplantation

2006

140

Advantages of Artificial Neural Networks (ANNs) as alternative modelling technique for data sets showing non-linear relationships using data from a galenical study on a solid dosage form

Jacques Bourquin, Heinz Schmidli, Peter van Hoogevest,

European Journal of Pharmaceutical Sciences

1998

139

Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients

Gilbert Lefèvre, G Sędek, S. S. Jhee,

Clinical Pharmacology & Therapeutics

2007

126

Population pharmacokinetics of imatinib mesylate in patients with chronic‐phase chronic myeloid leukaemia: results of a phase III study

Heinz Schmidli, Bin Peng, G‐J. Riviere,

British Journal of Clinical Pharmacology

2005

124

Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: Applications and Practical Considerations

Heinz Schmidli, Frank Bretz, Amy Racine,

Biometrical Journal

2006

124

Everolimus Therapeutic Concentration Range Defined from a Prospective Trial with Reduced-Exposure Cyclosporine in De Novo Kidney Transplantation

John M. Kovarik, Hélio Tedesco‐Silva, Julio Pascual,

Therapeutic Drug Monitoring

2004

98

A faunistic approach to assess potential side-effects of genetically modified <i>Bt</i> -Corn on non-target arthropods under field conditions

M. P. Candolfi, Keith Brown, Christoph Grimm,

Biocontrol Science and Technology

2004

95

Pharmacokinetics and electrocardiographic pharmacodynamics of artemether‐lumefantrine (Riamet<sup>®</sup>) with concomitant administration of ketoconazole in healthy subjects

Gilbert Lefèvre, Polly Carpenter, C. Souppart,

British Journal of Clinical Pharmacology

2002

83

Page 1